A Phase I clinical study of a subtype selective NMDA receptor negative allosteric modulator (NAM) for the treatment of treatment-resistant depression.

Trial Profile

A Phase I clinical study of a subtype selective NMDA receptor negative allosteric modulator (NAM) for the treatment of treatment-resistant depression.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs NMDA receptor modulators (Primary)
  • Indications Depressive disorders
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 26 Oct 2017 New trial record
    • 17 Oct 2017 According to a Cadent Therapeutics media release, Cadent Therapeutics has earned a milestone payment from Novartis for the initiation of this Phase 1 clinical study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top